丁苯酞联合倍他司汀治疗后循环缺血性眩晕患者的效果

Effects of Butylphthalide combined with Betahistine in treatment of patients with posterior circulation ischemic vertigo

目的:观察丁苯酞联合倍他司汀治疗后循环缺血性眩晕患者的效果。方法:选取2022年1月至2023年2月该院收治的88例后循环缺血性眩晕患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各44例。对照组采用倍他司汀治疗,研究组在对照组基础上联合丁苯酞软胶囊治疗。比较两组临床疗效、治疗前后血清学指标[降钙素基因相关肽(CGRP)、肌酸激酶同工酶(CK-MB)、脑钠肽(BNP)]水平、脑血流速度[脑前动脉(ACA)、椎基底动脉(BA)]、临床症状改善情况[眩晕障碍量表(DHI)评分、眩晕消失时间]及不良反应发生率。结果:研究组治疗总有效率为93.18%(41/44),高于对照组的75.00%(33/44),差异有统计学意义(P<0.05);两组CGRP、CK-MB及BNP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组ACA、BA血流速度均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);研究组眩晕消失时间短于对照组,差异有统计学意义(P<0.05);两组DHI评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丁苯酞联合倍他司汀治疗后循环缺血性眩晕患者,可提高临床疗效,降低血清学指标水平,加快脑血流速度,促进眩晕症状消失,效果优于倍他司汀治疗。

Objective:To observe effects of Butylphthalide combined with Betahistine in treatment of patients with posterior circulation ischemic vertigo.Methods:A prospective study was conducted on 88 patients with posterior circulation ischemic vertigo admitted to this hospital from January 2022 to February 2023.They were divided into control group and study group according to the random number table method,44 cases in each.The control group was treated with Betahistine,while the study group was treated with Butylphthalide soft capsules on the basis of that of the control group.The clinical efficacy,the serological indexes[calcitonin gene-related peptide(CGRP),creatine kinase isoenzyme(CK-MB),brain natriuretic peptide(BNP)]levels before and after the treatment,the cerebral blood flow velocity[anterior cerebral artery(ACA),vertebrobasilar artery(BA)],the improvement of clinical symptoms[dizziness handicap inventory(DHI)score,vertigo disappearance time],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 93.18%(41/44),which was higher than 75.00%(33/44)in the control group,and the difference was statistically significant(P<0.05).The levels of CGRP,CK-MB and BNP in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The blood flow velocities of ACA and BA in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The disappearance time of vertigo in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The DHI scores of the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Butylphthalide combined with Betahistine in the treatment of the patients with posterior circulation ischemic vertigo can improve the clinical efficacy,reduce the levels of serological indexes,accelerate the cerebral blood flow velocities,and promote the disappearance of vertigo symptoms.Moreover,it is superior to Betahistine treatment.